Donepezil hydrochloride is a second-generation cholinesterase (ChE) inhibitor used clinically for the treatment of mild to moderate Alzheimer's-type dementia. It enhances cholinergic neurotransmission by reversibly inhibiting acetylcholinesterase-mediated hydrolysis of acetylcholine, thereby increasing acetylcholine concentrations at receptor sites. It is the only drug that meets the U.S. Food and Drug Administration (FDA) guidelines for dementia treatment and is uniquely approved by both the U.S. FDA and the UK Medicines Control Agency (MCA) for the treatment of mild to moderate Alzheimer’s disease.